^
Association details:
| Biomarker: | CD20 positive |
|---|---|
| Cancer: | Diffuse Large B Cell Lymphoma |
| Drug: | nab-paclitaxel/rituximab nanoparticle (AR160) (Bcl2 inhibitor, CD20 inhibitor, Tubulin inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Antibody-targeted paclitaxel loaded nanoparticles for the treatment of CD20+ B-cell lymphoma
Excerpt:
In a mouse model of CD20+ lymphoma we show a profound anti-tumor effect that is curative in a majority of mice treated with AR160. Furthermore, we have shown that improved tumor efficacy is due to increased antibody-mediated drug deposition in the tumor. Clinical testing of AR160 is warranted to determine the full clinical relevance of this nano-antibody targeted chemotherapy.
DOI:
10.1038/srep45682
